ABP-450
Episodic Migraine
Key Facts
About AEON Biopharma
AEON Biopharma is a U.S.-based public company with a mission to broaden access to therapeutic botulinum toxins through the development of ABP-450, a branded biosimilar to AbbVie's BOTOX®. Its strategy leverages the established FDA biosimilar pathway, a validated manufacturing platform, and a proprietary 'Smart Injection Paradigm' to target high-value neurological and gastrointestinal disorders. While still pre-revenue, AEON has advanced ABP-450 into Phase 2 trials for episodic migraine and cervical dystonia, positioning itself as a potential disruptor in a market long constrained by limited competition and high costs.
View full company profileAbout AEON Biopharma
AEON Biopharma is a U.S.-based public company with a mission to broaden access to therapeutic botulinum toxins through the development of ABP-450, a branded biosimilar to AbbVie's BOTOX®. Its strategy leverages the established FDA biosimilar pathway, a validated manufacturing platform, and a proprietary 'Smart Injection Paradigm' to target high-value neurological and gastrointestinal disorders. While still pre-revenue, AEON has advanced ABP-450 into Phase 2 trials for episodic migraine and cervical dystonia, positioning itself as a potential disruptor in a market long constrained by limited competition and high costs.
View full company profileAbout AEON Biopharma
AEON Biopharma is a U.S.-based public company with a mission to broaden access to therapeutic botulinum toxins through the development of ABP-450, a branded biosimilar to AbbVie's BOTOX®. Its strategy leverages the established FDA biosimilar pathway, a validated manufacturing platform, and a proprietary 'Smart Injection Paradigm' to target high-value neurological and gastrointestinal disorders. While still pre-revenue, AEON has advanced ABP-450 into Phase 2 trials for episodic migraine and cervical dystonia, positioning itself as a potential disruptor in a market long constrained by limited competition and high costs.
View full company profileAbout AEON Biopharma
AEON Biopharma is a U.S.-based public company with a mission to broaden access to therapeutic botulinum toxins through the development of ABP-450, a branded biosimilar to AbbVie's BOTOX®. Its strategy leverages the established FDA biosimilar pathway, a validated manufacturing platform, and a proprietary 'Smart Injection Paradigm' to target high-value neurological and gastrointestinal disorders. While still pre-revenue, AEON has advanced ABP-450 into Phase 2 trials for episodic migraine and cervical dystonia, positioning itself as a potential disruptor in a market long constrained by limited competition and high costs.
View full company profileAbout AEON Biopharma
AEON Biopharma is a U.S.-based public company with a mission to broaden access to therapeutic botulinum toxins through the development of ABP-450, a branded biosimilar to AbbVie's BOTOX®. Its strategy leverages the established FDA biosimilar pathway, a validated manufacturing platform, and a proprietary 'Smart Injection Paradigm' to target high-value neurological and gastrointestinal disorders. While still pre-revenue, AEON has advanced ABP-450 into Phase 2 trials for episodic migraine and cervical dystonia, positioning itself as a potential disruptor in a market long constrained by limited competition and high costs.
View full company profileTherapeutic Areas
Other Episodic Migraine Drugs
| Drug | Company | Phase |
|---|---|---|
| CT-132 | Click Therapeutics | Phase 3 |